Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Jan;145(1):87-89.e1.
doi: 10.1016/j.jaci.2019.10.013. Epub 2019 Oct 24.

Eosinophilic gastrointestinal disease below the belt

Affiliations
Editorial

Eosinophilic gastrointestinal disease below the belt

Robert D Pesek et al. J Allergy Clin Immunol. 2020 Jan.

Abstract

Eosinophilic gastrointestinal diseases (EGIDs) are rare diseases of the gastrointestinal tract caused by allergic inflammation and gastrointestinal dysfunction. Initially described in 1978, recognition of these disorders has greatly increased over the past several decades. Thus far, eosinophilic esophagitis (EoE) has received the most focus, leading to significant advances in understanding of disease mechanisms, widely adopted guidelines for diagnosis and management, and ongoing clinical trials to provide expanded treatment options. EGIDs can affect other parts of the gastrointestinal tract and include eosinophilic gastritis (EG), eosinophilic gastroenteritis (EGE), and eosinophilic colitis (EC), yet these diseases are barely understood compared with EoE. Much of the research to date is limited to case series or single-center experiences, and there are no well-established guidelines for diagnosis or management. In this article the current state of EGIDs will be reviewed.

Keywords: Eosinophilic esophagitis; eosinophilic colitis; eosinophilic gastritis; eosinophilic gastroenteritis; eosinophilic gastrointestinal diseases.

PubMed Disclaimer

Conflict of interest statement

Disclosure of potential conflict of interest: R. D. Pesek is a consultant for Allakos. M. E. Rothenberg is a consultant for PulmOne, Spoon Guru, ClostraBio, Celgene, AstraZeneca, and Allakos; has an equity interest in the first 3 listed and royalties from reslizumab (Teva Pharmaceuticals), PEESSv2 (Mapi Research Trust), and UpToDate; and is an inventor of patents owned by Cincinnati Children’s Hospital Medical Center.

References

    1. Dellon ES, Liacouras CA, Molina-Infante J, Furuta GT, Spergel JM, Zevit N, et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference. Gastroenterology 2018;155:1022–33. - PMC - PubMed
    1. Moawad FJ. Eosinophilic esophagitis: incidence and prevalence. Gastrointest Endoscopy Clin N Am 2019;28:15–25. - PubMed
    1. O’Shea KM, Aceves SS, Dellon ES, Gupta SK, Spergel JM, Furuta GT, et al. Pathophysiology of eosinophilic esophagitis. Gastroenterology 2018;154:333–45. - PMC - PubMed
    1. Shoda T, Wen T, Aceves SS, Abonia JP, Atkins D, Bonis PA, et al. Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study. Lancet Gastroenterol Hepatol 2018;3: 477–88. - PMC - PubMed
    1. Warners MJ, Hindryckx P, Levesque BG, Parker CE, Shackelton LM, Khanna R, et al. Systematic review: disease activity indices in eosinophilic esophagitis. Am J Gastroenterol 2017;112:1658–69. - PubMed

Publication types

Supplementary concepts